Clinical trial
An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT02587715 is registered in ClinicalTrials.gov with Novo Cellular Medicine Institute LLP as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
- Lead sponsor
- Novo Cellular Medicine Institute LLP
- Phase
- Phase 1/2
- Overall status
- Unknown status
- Start date
- February 28, 2015
- Completion date
- February 28, 2017
- Enrollment
- 69 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.